TO O 1006
Alternative Names: TO-O-1006Latest Information Update: 03 Aug 2022
At a glance
- Originator Theratocular Biotek
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 28 Jul 2022 TO O 1006 is available for licensing as of 28 Jul 2022. https://www.theratocular.com.tw/en/about.php
- 21 Jul 2022 Preclinical trials in Dry age-related macular degeneration in Taiwan (Ophthalmic) Prior to July 2022